The NCCN ORP fosters innovation and knowledge discovery that improve the lives of patients with cancer.
Guiding Principles:
NCCN and Pfizer Investigator Sponsored Research for Understanding the Mechanisms and Formulating the Optimal Management of Hematological Toxicity of PARPi in the Treatment of Prostate Cancer – Proposal Submission Deadline Extended until Wednesday, September 18, 2024. Now open to all investigators in the United States.
Now Accepting Abstracts for the 2025 NCCN Annual Conference General Poster Session - Submit an abstract by Wednesday, October 30, 2024.
View the NCCN ORP Press Releases
View the NCCN ORP Scientific Publications
View the NCCN ORP Disclosure Policy